Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value

Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2007 2008 2009 2010 2011 2012 TTM 2013E 2014E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -42.0%

FINANCIAL BRIEF: For the six months ended 30 June 2013, Silence Therapeutics plc revenues increased 11% to L41K. Net loss decreased 86% to L3.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects RNAi therapeutics segment loss decrease of 89% to L2.4M. Basic Earnings per Share excluding Extraordinary Items increased from -L1.91 to -L0.08. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

Recent History
Latest interim period (ended 30th Jun '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2013
31st Dec 2014

Price Target: 496 (+92.81% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (£) (£) (p) (£)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Silence Therapeutics
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Canaccord Genuity Julie Simmonds , N+1 Singer Jens Lindqvist , Virtua Research Pravin Gondhale , and 1 unnamed other

Silence Therapeutics plc (Silence Therapeutics) is engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company’s product, Atu027, is in a phase Ib/2a clinical trial. RNAi platform is built around the AtuRNAi technology and based on stabilization technology, and specific small interfering (siRNA) molecules. A delivery platform using molecules, such as AtuFECT to target a range of organs in the field with: AtuPLEX (for endothelial cells of the vascular system); DBTC (for hepatocytes and hepathic vascular system), and DACC (for vascular endothelial cells of the lung).

Directors: Ali Mortazavi (CEO) , Tim Freeborn (Fin. Dir.) 53, Jia Huey Cheng (COO) 37, Jorg Kaufmann (CSO) , Michael Khan (Other) ,

No. of Employees: 34 No. of Shareholders: n/a

Last Annual December 31st, 2012
Last Interim June 30th, 2013
Shares in Issue 47,061,554
Free Float 17.6m (37.5%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

SLN Share Price Performance SLN Quote
-2.3  -0.9%
Traded 4:35pm · Minimum 15 min delayed · NMS: 0.750k

Latest SLN News Announcements (delayed)

Upcoming SLN Events
Tuesday 24th June, 2014 (estimate)
Silence Therapeutics PLC Annual General Meeting
Monday 22nd September, 2014 (estimate)
Interim 2014 Silence Therapeutics PLC Earnings Release

Recent ↓
Wednesday 19th March, 2014
Preliminary 2013 Silence Therapeutics PLC Earnings Release
Thursday 27th February, 2014
Silence Therapeutics PLC Year End Trading Update
Monday 18th November, 2013
Silence Therapeutics PLC Investor Day
Sunday 3rd November, 2013
Silence Therapeutics plc at EBD Group China Forum
Monday 23rd September, 2013
Interim 2013 Silence Therapeutics plc Earnings Release
Tuesday 17th September, 2013
Silence Therapeutics plc at EBD Group BioPharm America
Wednesday 26th June, 2013
Silence Therapeutics PLC Annual General Meeting
Wednesday 29th May, 2013
Preliminary 2012 Silence Therapeutics plc Earnings Release
Tuesday 30th April, 2013
Silence Therapeutics PLC Reverse Split For SLN.L
Tuesday 23rd April, 2013
Silence Therapeutics PLC General Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.

Should you buy SLN

Access SLN Analytics Now!